The fifteen members of the BCL2 family that are expressed in gynaecologic cancers (BCL2, BCL2L1, BCL2L2, MCL1, BAX, BAK1, BAD, BOK, BCL2L11, BMF, BID, NOXA, HRK, BBC3 and BIK) present aberrant expression in many cancers and may be associated with chromosomal translocations, gene amplification, upregulated gene transcription, altered post‐translational processing and tumour progression.6, 8, 9. This evidence concerns the gene BOK and neoplasm.